These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 23957985)

  • 21. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
    Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
    Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.
    Senff NJ; Hoefnagel JJ; Neelis KJ; Vermeer MH; Noordijk EM; Willemze R;
    Arch Dermatol; 2007 Dec; 143(12):1520-6. PubMed ID: 18087001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinical findings, histology, and immunohistochemistry.
    Felcht M; Booken N; Stroebel P; Goerdt S; Klemke CD
    J Am Acad Dermatol; 2011 Jan; 64(1):135-43, 143.e1-4. PubMed ID: 21167409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
    Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
    Hristov AC; Tejasvi T; Wilcox RA
    Am J Hematol; 2023 Aug; 98(8):1326-1332. PubMed ID: 37434388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The histomorphologic spectrum of primary cutaneous diffuse large B-cell lymphoma: a study of 79 cases.
    Plaza JA; Kacerovska D; Stockman DL; Buonaccorsi JN; Baillargeon P; Suster S; Kazakov DV
    Am J Dermatopathol; 2011 Oct; 33(7):649-55; quiz 656-8. PubMed ID: 21937906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma.
    Lang CCV; Ramelyte E; Dummer R
    Front Oncol; 2020; 10():1163. PubMed ID: 32850331
    [No Abstract]   [Full Text] [Related]  

  • 28. Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management.
    Fava P; Roccuzzo G; Alberti-Violetti S; Grandi V; Pileri A; Pimpinelli N; Berti E; Quaglino P
    Presse Med; 2022 Mar; 51(1):104109. PubMed ID: 35026390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous B-cell lymphoma: important diagnostic tools.
    Ferenczi K
    G Ital Dermatol Venereol; 2010 Jun; 145(3):361-73. PubMed ID: 20461044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Gastric malignant lymphoma].
    Yoshita H; Sugiyama T
    Nihon Rinsho; 2012 Jul; 70(7):1253-62. PubMed ID: 22844813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary cutaneous B-cell lymphoma: classification and treatment.
    Willemze R
    Curr Opin Oncol; 2006 Sep; 18(5):425-31. PubMed ID: 16894288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.
    Nicolay JP; Wobser M
    J Dtsch Dermatol Ges; 2016 Dec; 14(12):1207-1224. PubMed ID: 27992127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal AP-1 protein expression in primary cutaneous B-cell lymphomas.
    Mao X; Orchard G
    Br J Dermatol; 2008 Jul; 159(1):145-51. PubMed ID: 18460027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response.
    Graham PM; Richardson AS; Schapiro BL; Saunders MD; Stewart DM
    JAAD Case Rep; 2018 May; 4(4):305-309. PubMed ID: 29693055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indurated Plaques on the Legs: Think Lymphoma.
    Watts-Santos A; Cuellar-Barboza A; Ramos-Cavazos CJ; Villarreal-Martinez A; Ocampo-Candiani J; Herz-Ruelas ME
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):114-115. PubMed ID: 34477080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges.
    Wobser M; Kneitz H; Bröcker EB; Becker JC
    J Dtsch Dermatol Ges; 2011 Mar; 9(3):204-11. PubMed ID: 21122066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD30 expression in cutaneous B-cell lymphomas.
    Afolayan-Oloye O; Zhao L; Tejasvi T; Chan MP; Harms PW; Fullen DR; Wilcox RA; Hristov AC
    J Cutan Pathol; 2023 Sep; 50(9):819-827. PubMed ID: 37290910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literature.
    Olszewska-Szopa M; Sobas M; Laribi K; Bao Perez L; Drozd-Sokołowska J; Subocz E; Joks M; Zduniak K; Gajewska M; de Nalecz AK; Romejko-Jarosińska J; Kumiega B; Waszczuk-Gajda A; Wróbel T; Czyz A
    Acta Oncol; 2021 Oct; 60(10):1361-1368. PubMed ID: 34346830
    [No Abstract]   [Full Text] [Related]  

  • 39. Programmed death-1 expression in cutaneous B-cell lymphoma.
    Çetinözman F; Koens L; Jansen PM; Willemze R
    J Cutan Pathol; 2014 Jan; 41(1):14-21. PubMed ID: 24151955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells.
    Felcht M; Heck M; Weiss C; Becker JC; Dippel E; Müller CS; Nashan D; Sachse MM; Nicolay JP; Booken N; Goerdt S; Klemke CD
    Br J Dermatol; 2012 Aug; 167(2):348-58. PubMed ID: 22512270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.